Androgen receptor in relation to progesterone receptor (AR/PR ratio) in non-metastatic hormonal positive, Her2neu negative breast cancer
Amine, M., Hefni, A., Younis, S., Elsaba, T., Zaky, A., Zedan, A. (2024). Androgen receptor in relation to progesterone receptor (AR/PR ratio) in non-metastatic hormonal positive, Her2neu negative breast cancer. EKB Journal Management System, 7(1), 572-579. doi: 10.21608/svuijm.2021.78961.1182
Maged A.F. Amine; Ahmed Mubarak Hefni; Shimaa R. Younis; Tarek M Elsaba; Amen H. Zaky; Ashraf Zedan. "Androgen receptor in relation to progesterone receptor (AR/PR ratio) in non-metastatic hormonal positive, Her2neu negative breast cancer". EKB Journal Management System, 7, 1, 2024, 572-579. doi: 10.21608/svuijm.2021.78961.1182
Amine, M., Hefni, A., Younis, S., Elsaba, T., Zaky, A., Zedan, A. (2024). 'Androgen receptor in relation to progesterone receptor (AR/PR ratio) in non-metastatic hormonal positive, Her2neu negative breast cancer', EKB Journal Management System, 7(1), pp. 572-579. doi: 10.21608/svuijm.2021.78961.1182
Amine, M., Hefni, A., Younis, S., Elsaba, T., Zaky, A., Zedan, A. Androgen receptor in relation to progesterone receptor (AR/PR ratio) in non-metastatic hormonal positive, Her2neu negative breast cancer. EKB Journal Management System, 2024; 7(1): 572-579. doi: 10.21608/svuijm.2021.78961.1182

Androgen receptor in relation to progesterone receptor (AR/PR ratio) in non-metastatic hormonal positive, Her2neu negative breast cancer

SVU-International Journal of Medical Sciences
Article 91, Volume 7, Issue 1, January 2024, Page 572-579  XML PDF (389.77 K)
Document Type: Original research articles
DOI: 10.21608/svuijm.2021.78961.1182
View on SCiNiTO View on SCiNiTO
Authors
Maged A.F. Amine1; Ahmed Mubarak Hefni1; Shimaa R. Younis email 1; Tarek M Elsaba2; Amen H. Zaky1; Ashraf Zedan1
1Department of Medical Oncology and Hematology Department, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
2Department of Pathology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
Abstract
Background: The impact of estrogen/progesterone receptors (ER/PR) is well-established with respect to therapy and prognosis of breast carcinoma. However, the role of androgen receptor (AR) expression is varying among breast cancer subtypes.
Objectives: The objective of this study is evaluating relation between androgen receptor to progesterone receptor in non-metastatic hormonal positive Her2-neu negative breast cancer patients.
Patients and methods: This study included 100 female patients with breast carcinoma, whose hormone receptor status data were available. Demographic and histopathologic details were retrieved. Immunohistochemistry for AR was done and considered positive if >10% of tumor cells showed nuclear staining.
Results: We evaluated 100 female patients with primary breast cancer by using immunohistochemistry. Of the 100 cases, 51 cases had an AR/PR ratio<1.63 and 49 cases had an AR/PR ratio ≥1.63. In the descriptive analysis, patients with a higher AR/PR ratio carried early disease stage and they frequently had negativity for perineural invasion (p value<0.005).
 Conclusion: There is no significant association between AR/PR ratio with overall survival and disease free survival. AR/PR could be used to identify patients with different prognosis, their real value needs to be better clarified in different BC settings through prospective studies and larger number of patients.
Keywords
Androgen receptor; Breast carcinoma; Androgen receptor /progesterone receptor
Statistics
Article View: 276
PDF Download: 6